PharmiWeb Solutions Talking to Jean-Luc Bélingard, CEO of Ipsen
Summary
We're having a fascinating day at the Financial Times Global Pharmaceutical and Biotechnology conference on London.One of the most interesting commentaries today came from Jean-Luc Bélingard, CEO of Ipsen. Jean-Luc stated that in his view, for the pharmaceutical segment, ‘Demand is infinite’ – with no therapeutic cure for the mahority of diseases. Take diabetes for example – we can treat it, to a large extent, but we can’t cure it.
This makes the pharma and interesting market, and this, with all of the other changes and challenges in the segment, does pose challenges for the survival and growth of individual pharmaceutical corporates.
Paul Hartigan, CEO of PharmiWeb Solutions, asked Jean-Luc if he was confident therefore in the future for the industry.
(Mr Bélingard started his career at Merck, Sharp and Dohme. He then joined the F. Hoffman-La Roche Group where his last position was CEO of Roche Diagnostics and member of the Executive Committee of the F. Hoffman-La Roche Group. In 1999, Mr Bélingard became CEO of bioMérieux-Pierre Fabre. Since 2002, Mr Bélingard is Chairman and Chief Executive Officer of the Ipsen Group).
